Syngene provides a range of services in the areas of diagnostics as well as therapeutic and vaccine R&D.
Syngene has an excellent track record in expression and purification of protein reagents and antibodies from various expression systems – bacterial, mammalian, insect cells, and yeast. We make and ship more than 2000 proteins a year to our clients.
Syngene produces SARS-CoV-2 specific, primers and probes. We provide custom oligos defined by our customers, as well as those mentioned in protocols recommended by WHO, CDC and ICMR.
Syngene offers SARS-CoV-2 in-vitro and in-vivo research, in partnership with Foundation for Neglected Disease Research (FNDR). This non-exclusive partnership, aims to provide a range of non-BSL3 and BSL3 in vitro and in vivo capabilities to facilitate a wide variety of studies on SARS-CoV-2, and prepare us for the next wave of the corona virus pandemic.
Syngene collaborates and provides technical assistance to vaccine manufacturers for their virosome technology-based COVID-19 vaccine development. As part of the collaboration, Syngene will run animal immunization studies to validate the specific immune response to potentially create antibodies.